TITLE

Emergency correction of coagulation before major surgery in two elderly patients on oral anticoagulation

AUTHOR(S)
Angelo, Marzia; Gutmann, Bernhard; Adami, Michele; Zagler, Bernd; Zelger, Anton; Pechlaner, Christoph; Wiedermann, Christian J.
PUB. DATE
January 2007
SOURCE
Thrombosis Journal;2007, Vol. 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recommendations for urgent reversal of oral anticoagulation with vitamin K1 antagonists are largely derived from case series employing empirical dosing regimens with vitamin K1 and prothrombin complex concentrates. Data on the use of prothrombin complex concentrates in this indication are scarce in the elderly who are at high risk of both hemorrhagic and thrombotic complications. The two cases presented here describe patients older than 75 years who underwent rapid International Normalized Ratio (INR) reversal with prothrombin complex concentrates for surgical treatment of a bleeding ruptured spleen and for emergency surgery of a dissecting aorta. Both patients had their INRs rapidly corrected to ≤ 1.6 and underwent operation without complications. Evidence on treatment of patients who present with elevated INR and who have major bleeding or need to undergo emergency surgery is based mainly on observational studies. The two elderly patients presented here underwent successful emergency surgery after their INRs had been corrected with the intravenous use of vitamin K1 in combination with prothrombin complex concentrate that was administered according to current guideline recommendations.
ACCESSION #
28810435

 

Related Articles

  • Haemorrhagic Complications of Vitamin K Antagonists in the Elderly: Risk Factors and Management. Pautas, Eric; Gouin-Thibault, Isabelle; Debray, Matthieu; Gaussem, Pascale; Siguret, Virginie // Drugs & Aging;2006, Vol. 23 Issue 1, p13 

    In patients >75 years of age, the two main indications for oral anticoagulant therapy with vitamin K antagonists (VKAs) are treatment of venous thromboembolic disease and prevention of systemic embolism in patients with nonvalvular atrial fibrillation. In both indications, a target International...

  • Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants. Romualdi, Erica; Rancan, Elena; Siragusa, Sergio; Ageno, Walter // Current Pharmaceutical Design;10/21/2010, Vol. 16 Issue 31, p3478 

    No abstract available.

  • PITFALLS IN ANTICOAGULANT THERAPY FOR MYOCARDIAL INFARCTION. Moore, Charles B. // Angiology;Jan1964, Vol. 15 Issue 1, p27 

    The additional evidence to the growing belief that prolonged oral anticoagulant therapy is safe and practical also requires a discussion of the pitfalls in the management of these patients which includes: 1. Difficulties with laboratory determinations and their inability at times to reflect the...

  • Careful management can reduce the risk of bleeding in elderly patients receiving vitamin K antagonist (VKA) therapy.  // Drugs & Therapy Perspectives;Dec2006, Vol. 22 Issue 12, p23 

    Vitamin K antagonists are often under prescribed in older patients because physicians fear an increased risk of major bleeding. Nevertheless, the benefits of therapy still appear to outweigh the risks. The possibility of over- or under-anticoagulation may be minimising by using VKA induction...

  • Neue Antikoagulanzien, neue Notfälle? Djalali, Sima // Praxis (16618157);7/24/2013, Vol. 102 Issue 15, p945 

    No abstract available.

  • Treating Anticoagulant-Associated Bleeding. Shuman, Jill; Sarode, Ravi; Dzik, Sunny // MD Conference Express;Aug2015, Vol. 15 Issue 21, p26 

    Agents that reverse the effect of vitamin K antagonists include plasma, vitamin K, and prothrombin complex concentrate. Hemostasis is most likely to be achieved by using a prothrombin complex concentrate. Guidelines for reversing the effect of direct-acting anticoagulants are based on guidelines...

  • The progress of prothrombin time measurement. Horsti, Juha // Hematology Reviews;2009, Vol. 1 Issue 2, p99 

    Warfarin is the most widely used medicine for oral anticoagulant therapy (OAT). It inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver and results in the production of inactive or partially active versions of these factors. Inactive coagulation factors interfere with...

  • On the Treatment of New Oral Anticoagulant-Associated Gastrointestinal Hemorrhage. Holster, I. Lisanne; Hunfeld, Nicole G. M.; Kuipers, Ernst J.; Kruip, Marieke J. H. A.; Tjwa, Eric T. T. L. // Journal of Gastrointestinal & Liver Diseases;Jun2013, Vol. 22 Issue 2, p229 

    The recently introduced new oral anticoagulants (nOAC) carry a higher gastrointestinal bleeding risk compared to traditional antithrombotic therapy. Current diagnostic coagulation tests are not accurate enough to determine the level of coagulopathy. Besides that, the lack of a specific antidote...

  • Rapid vitamin K antagonist reversal.  // Africa Health;Jul2015, Vol. 37 Issue 5, p36 

    The article discusses the efficacy of rapid reversal of vitamin K antagonist (VKA)-induced anticoagulation in patients who need urgent surgical or invasive procedures.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics